Protein expression trends of DNMT1 in gastrointestinal diseases: From benign to precancerous lesions to cancer

Figure 1 Expression of DNMT1 in different gastric diseases (×20). A: Chronic superficial gastritis [negative expression; score, 0 (+)]; B: Atrophic gastritis with intestinal metaplasia [moderately positive expression; score, 2 (++)]; C: Gastric low-grade intraepithelial neoplasia [moderately positive expression; score, 4 (++)]; D: Gastric high-grade intraepithelial neoplasia [strongly positive expression; score, 6 (+++)]; E: Early gastric cancer [strongly positive expression; score, 9 (+++)].

Figure 2 Comparison of DNMT1 expression in different gastric disease groups.

Figure 3 Expression of DNMT1 in different intestinal diseases (×20). A: Normal intestinal mucosa [negative expression; score, 0 (+)]; B: Intestinal low-grade intraepithelial neoplasia [moderate expression; score, 2 (++)]; C: Intestinal high-grade intraepithelial neoplasia [strong expression; score, 6 (+++)]; D: Early colorectal cancer [strong expression; score, 9 (+++)].

Figure 4 Comparison of DNMT1 expression in different intestinal disease groups.